Alcista
$32.55
Precio del escenario
$35.390
-0.552 (-1.56%)Al cierre
Omnicell, Inc. is a healthcare technology provider focused on autonomous medication management, by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities. The Company is focused on helping its customers define and deliver a medication management strategy designed for pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. It provides a range of points of care medication and supplies dispensing systems, including automated systems and offers advanced automation solutions, including robotics designed to automate work, streamline workflows, and reduce human error. It provides central pharmacy automation solutions for both medication dispensing and IV compounding and provides patient engagement solutions.
Omnicell Inc is a good buy right now, trading at $35.82 with a forward P/E of 29.50, indicating potential for growth. The recent RSI of 72.54 suggests strong momentum, while the stock has gained 6.61% over the last five days, reflecting positive short-term performance. However, insider selling has increased by 151.38%, which is a risk to consider.
Piper Sandler
$45
2026-08-03
Piper Sandler
2026-08-03
Precio objetivo
$45
KeyBanc
$65
2026-07-31
KeyBanc
2026-07-31
Precio objetivo
$65
Wells Fargo
$50
2026-07-31
Wells Fargo
2026-07-31
Precio objetivo
$50
Craig-Hallum
$55
2026-04-29
Craig-Hallum
2026-04-29
Precio objetivo
$55
KeyBanc
$70
2026-04-29
KeyBanc
2026-04-29
Precio objetivo
$70
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Omnicell Integrates TraceLink's DSCSA Compliance Solution for Enhanced Pharmacy Operations

TraceLink and Omnicell Integration Enhances Pharmacy Management Efficiency

Omnicell to Present at Wells Fargo Healthcare Conference

Omnicell Executive Sells Shares to Meet Tax Obligations

Omnicell Q2 2026 Earnings Call Highlights
Omnicell, Inc. is a healthcare technology provider focused on autonomous medication management, by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities. The Company is focused on helping its customers define and deliver a medication management strategy designed for pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. It provides a range of points of care medication and supplies dispensing systems, including automated systems and offers advanced automation solutions, including robotics designed to automate work, streamline workflows, and reduce human error. It provides central pharmacy automation solutions for both medication dispensing and IV compounding and provides patient engagement solutions. It operates in the Healthcare sector (ELECTRONIC COMPUTERS industry).
Omnicell Inc is a good buy right now, trading at $35.82 with a forward P/E of 29.50, indicating potential for growth. The recent RSI of 72.54 suggests strong momentum, while the stock has gained 6.61% over the last five days, reflecting positive short-term performance. However, insider selling has increased by 151.38%, which is a risk to consider.
8 analysts cover OMCL: 5 rate it Buy, 3 Hold and 0 Sell. The average price target is 54.20.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.